Hepatotoxic effects of methotrexate

作者：Evan M. Hersh, Vernon G. Wong, Edward S. Henderson, Emil J. Freireich · 发表于：Cancer · 年份：1966 · DOI：10.1002/1097-0142(196604)19:4<600::aid-cncr2820190420>3.0.co;2-3 · 被引用次数：133 · 研究领域：Acute Lymphoblastic Leukemia research、Chronic Myeloid Leukemia Treatments、Chemotherapy-induced organ toxicity mitigation

Hepatotoxicity of methotrexate (MTX) therapy was studied in 22 patients. During intensive MTX therapy, values for SGOT, SGPT, LDH and BSP were 140 μ, 315 μ, 753 μ and 13% with control values of 13.5 μ, 20.5 μ, 379 μ and 4%, respectively. During intermittent therapy these values were 50 μ, 110 μ, 544 μ and 10% with controls of 13 μ, 15 μ, 355 μ and 3%. Other liver function tests remained normal. After cessation of intermittent therapy, recovery occurred in one month. Liver biopsies revealed a chronic portal inflammatory reaction in 7/10. Methotrexate can be used in nonmalignant disorders provided that careful control of its toxic side effects is maintained.